133 related articles for article (PubMed ID: 21753234)
1. A model to estimate the outcome of prostate cancer photodynamic therapy with TOOKAD Soluble WST11.
Betrouni N; Lopes R; Puech P; Colin P; Mordon S
Phys Med Biol; 2011 Aug; 56(15):4771-83. PubMed ID: 21753234
[TBL] [Abstract][Full Text] [Related]
2. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
Azzouzi AR; Barret E; Moore CM; Villers A; Allen C; Scherz A; Muir G; de Wildt M; Barber NJ; Lebdai S; Emberton M
BJU Int; 2013 Oct; 112(6):766-74. PubMed ID: 24028764
[TBL] [Abstract][Full Text] [Related]
3. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.
Moore CM; Azzouzi AR; Barret E; Villers A; Muir GH; Barber NJ; Bott S; Trachtenberg J; Arumainayagam N; Gaillac B; Allen C; Schertz A; Emberton M
BJU Int; 2015 Dec; 116(6):888-96. PubMed ID: 24841929
[TBL] [Abstract][Full Text] [Related]
4. Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning.
Betrouni N; Boukris S; Benzaghou F
Lasers Med Sci; 2017 Aug; 32(6):1301-1307. PubMed ID: 28569345
[TBL] [Abstract][Full Text] [Related]
5. Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.
Azzouzi AR; Lebdai S; Benzaghou F; Stief C
World J Urol; 2015 Jul; 33(7):937-44. PubMed ID: 25786708
[TBL] [Abstract][Full Text] [Related]
6. Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States.
Taneja SS; Bennett J; Coleman J; Grubb R; Andriole G; Reiter RE; Marks L; Azzouzi AR; Emberton M
J Urol; 2016 Oct; 196(4):1096-104. PubMed ID: 27291652
[TBL] [Abstract][Full Text] [Related]
7. Endoscopic vascular targeted photodynamic therapy with the photosensitizer WST11 for benign prostatic hyperplasia in the preclinical dog model.
Chevalier S; Cury FL; Scarlata E; El-Zayat E; Hamel L; Rocha J; Zouanat FZ; Moussa S; Scherz A; Elhilali M; Anidjar M
J Urol; 2013 Nov; 190(5):1946-53. PubMed ID: 23680311
[TBL] [Abstract][Full Text] [Related]
8. Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).
Noweski A; Roosen A; Lebdai S; Barret E; Emberton M; Benzaghou F; Apfelbeck M; Gaillac B; Gratzke C; Stief C; Azzouzi AR
Eur Urol Focus; 2019 Nov; 5(6):1022-1028. PubMed ID: 29661587
[TBL] [Abstract][Full Text] [Related]
9. TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer.
Azzouzi AR; Barret E; Bennet J; Moore C; Taneja S; Muir G; Villers A; Coleman J; Allen C; Scherz A; Emberton M
World J Urol; 2015 Jul; 33(7):945-53. PubMed ID: 25712310
[TBL] [Abstract][Full Text] [Related]
10. Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses.
Trachtenberg J; Weersink RA; Davidson SR; Haider MA; Bogaards A; Gertner MR; Evans A; Scherz A; Savard J; Chin JL; Wilson BC; Elhilali M
BJU Int; 2008 Aug; 102(5):556-62. PubMed ID: 18494829
[TBL] [Abstract][Full Text] [Related]
11. Preclinical study of the novel vascular occluding agent, WST11, for photodynamic therapy of the canine prostate.
Chevalier S; Anidjar M; Scarlata E; Hamel L; Scherz A; Ficheux H; Borenstein N; Fiette L; Elhilali M
J Urol; 2011 Jul; 186(1):302-9. PubMed ID: 21600602
[TBL] [Abstract][Full Text] [Related]
12. Effects of Pd-bacteriopheophorbide (TOOKAD)-mediated photodynamic therapy on canine prostate pretreated with ionizing radiation.
Huang Z; Chen Q; Trncic N; LaRue SM; Brun PH; Wilson BC; Shapiro H; Hetzel FW
Radiat Res; 2004 Jun; 161(6):723-31. PubMed ID: 15161347
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of localized prostate cancer by vascular-targeted photodynamic therapy with WST11].
Lebdai S; Martin F; Bigot P; Azzouzi AR
Prog Urol; 2014 Nov; 24(14):911-4. PubMed ID: 25195031
[TBL] [Abstract][Full Text] [Related]
14. Studies of a vascular-acting photosensitizer, Pd-bacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer.
Huang Z; Chen Q; Luck D; Beckers J; Wilson BC; Trncic N; Larue SM; Blanc D; Hetzel FW
Lasers Surg Med; 2005 Jun; 36(5):390-7. PubMed ID: 15856509
[TBL] [Abstract][Full Text] [Related]
15. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response.
Trachtenberg J; Bogaards A; Weersink RA; Haider MA; Evans A; McCluskey SA; Scherz A; Gertner MR; Yue C; Appu S; Aprikian A; Savard J; Wilson BC; Elhilali M
J Urol; 2007 Nov; 178(5):1974-9; discussion 1979. PubMed ID: 17869307
[TBL] [Abstract][Full Text] [Related]
16. Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts.
Koudinova NV; Pinthus JH; Brandis A; Brenner O; Bendel P; Ramon J; Eshhar Z; Scherz A; Salomon Y
Int J Cancer; 2003 May; 104(6):782-9. PubMed ID: 12640688
[TBL] [Abstract][Full Text] [Related]
17. Histopathology of prostate tissue after vascular-targeted photodynamic therapy for localized prostate cancer.
Eymerit-Morin C; Zidane M; Lebdai S; Triau S; Azzouzi AR; Rousselet MC
Virchows Arch; 2013 Oct; 463(4):547-52. PubMed ID: 23948957
[TBL] [Abstract][Full Text] [Related]
18. An image guided treatment platform for prostate cancer photodynamic therapy.
Betrouni N; Colin P; Puech P; Villers A; Mordon S
Annu Int Conf IEEE Eng Med Biol Soc; 2013; 2013():370-3. PubMed ID: 24109701
[TBL] [Abstract][Full Text] [Related]
19. Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer.
Davidson SR; Weersink RA; Haider MA; Gertner MR; Bogaards A; Giewercer D; Scherz A; Sherar MD; Elhilali M; Chin JL; Trachtenberg J; Wilson BC
Phys Med Biol; 2009 Apr; 54(8):2293-313. PubMed ID: 19305043
[TBL] [Abstract][Full Text] [Related]
20. Treatment Effects of WST11 Vascular Targeted Photodynamic Therapy for Urothelial Cell Carcinoma in Swine.
Murray KS; Winter AG; Corradi RB; LaRosa S; Jebiwott S; Somma A; Takaki H; Srimathveeravalli G; Lepherd M; Monette S; Kim K; Scherz A; Coleman JA
J Urol; 2016 Jul; 196(1):236-43. PubMed ID: 26860792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
